Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 16/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22758761 | 1.00 | ATG7 (0.53) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20141916 | 0.92 | ATG7 (0.44) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22758807 | 0.92 | ATG7 (0.44) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20141915 | 0.92 | ATG7 (0.44) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20141617 | 0.91 | ATG7 (0.50) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22758835 | 0.91 | ATG7 (0.50) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20142620 | 0.86 | ATG7 (0.50) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20142167 | 0.86 | PI4KA (0.44) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20142334 | 0.86 | ADK (0.49) | ATG7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20142545 | 0.86 | ADK (0.49) | ATG7PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2018089786-A1 | ATG7 INHIBITORS AND THE USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | ATG7, BECN1, SQSTM1 | ATG7 1/4885PI4KA 1861/4885PI4K2B 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.